Abstract | OBJECTIVE: METHODS: HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires. RESULTS: The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates. CONCLUSION: The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
|
Authors | Darko Kastelan, Tonko Vlak, Petar Lozo, Marina Gradiser, Sime Mijic, Tatjana Nikolic, Blazenka Miskic, Dolores Car, Gordana Tajsic, Tina Dusek, Zrinka Jajic, Frane Grubisic, Tamara Poljicanin, Miro Bakula, Fedja Dzubur, Matilda Strizak-Ujevic, Mira Kadojic, Maja Radman, Maja Vugrinec, Zeljka Kuster, Marijeta Pekez, Endi Radovic, Ljubica Labar, Zeljka Crncevic-Orlic, Mirko Korsic |
Journal | Endocrine research
(Endocr Res)
Vol. 35
Issue 4
Pg. 165-73
( 2010)
ISSN: 1532-4206 [Electronic] England |
PMID | 20868288
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
|
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Ibandronic Acid
|
Topics |
- Aged
- Bone Density Conservation Agents
(administration & dosage)
- Chi-Square Distribution
- Diphosphonates
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Ibandronic Acid
- Middle Aged
- Osteoporosis, Postmenopausal
(drug therapy, psychology)
- Prospective Studies
- Quality of Life
- Surveys and Questionnaires
|